Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Arovella Therapeutics Limited ( (AU:ALA) ) has shared an update.
Arovella Therapeutics Limited has disclosed that director Gary Phillips ceased to be a director of the company on 9 February 2026. The filing notes that at the time of his departure, Phillips held indirect interests comprising 788,888 fully paid ordinary shares and 3,732,000 options in the company.
The notice confirms that Phillips had no directly registered shareholdings or contractual interests disclosed at the time of cessation. This change in the board’s composition may be of interest to shareholders monitoring governance, leadership stability and potential future strategic direction at Arovella Therapeutics.
The most recent analyst rating on (AU:ALA) stock is a Hold with a A$0.10 price target. To see the full list of analyst forecasts on Arovella Therapeutics Limited stock, see the AU:ALA Stock Forecast page.
More about Arovella Therapeutics Limited
Arovella Therapeutics Limited is a company listed on the ASX, operating in the biotechnology and therapeutics sector. The company focuses on developing medical treatments and related technologies, positioning itself within the broader healthcare and life sciences market.
Average Trading Volume: 1,038,715
Technical Sentiment Signal: Hold
Current Market Cap: A$108.1M
Find detailed analytics on ALA stock on TipRanks’ Stock Analysis page.